Successful rechallenge with reduced dose of erlotinib in a patient with lung adenocarcinoma who developed erlotinib-associated leukocytoclastic vasculitis: A case report

Oncology Letters

Volumn 3, Issue 6, 2012, Pages 1280-1282

  Su, Bo An ^a   Shen, Wan Lin ^a   Chang, Sheng Tsung ^a   Feng, Li Yia ^b   Wu, Chia Jung ^a   Feng, Yin Hsun ^a,c  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b NATIONAL KAOHSIUNG UNIVERSITY OF HOSPITALITY AND TOURISM   (Taiwan)

^c CHUNG HWA UNIVERSITY OF MEDICAL TECHNOLOGY   (Taiwan)

Author keywords

Erlotinib; Leukocytoclastic vasculitis; Lung cancer

Indexed keywords

ANTIBIOTIC AGENT; BEVACIZUMAB; ERLOTINIB; STEROID;

ADULT; ARTICLE; BONE BIOPSY; BONE METASTASIS; BONE PAIN; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DERMIS; DRUG DOSE REDUCTION; DRUG RECHALLENGE; DRUG WITHDRAWAL; ERYTHROCYTE; FACE; FEMALE; HISTOPATHOLOGY; HUMAN; LEUKOCYTOCLASTIC VASCULITIS; LIMB; LUNG NON SMALL CELL CANCER; NEUTROPHIL; PAPULE; PURPURIC RASH; PUSTULE; SCALP; SKIN BIOPSY; SKIN ULCER; STEROID THERAPY; TREATMENT RESPONSE; TRUNK; ULCER HEALING;

EID: 84859470590     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.647     Document Type: Article

References (6)

1. Ciardiello F, De Vita F, Orditura M, De Placido S and Tortora G: Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials. Expert Opin Emerg Drugs 8: 501-514, 2003.
2. Segaert S and Van Cutsem E: Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 16: 1425-1433, 2005.
3. Segaert S, Tabernero J, Chosidow O, et al: The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies. J Dtsch Dermatol Ges 3: 599-606, 2005.
4. Carlson JA: The histological assessment of cutaneous vasculitis. Histopathology 56: 3-23, 2010.
5. Boeck S, Wollenberg A and Heinemann V: Leukocytoclastic vasculitis during treatment with the oral EGFR tyrosine kinase inhibitor erlotinib. Ann Oncol 18: 1582-1583, 2007.
6. Kubota K, Nishiwaki Y, Tamura T, et al: Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase & study. J Thorac Oncol 3: 1439-1445, 2008.